(NASDAQ: CDMO) Avid Bioservices's forecast annual revenue growth rate of 12.56% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 60.26%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.39%.
Avid Bioservices's revenue in 2024 is $140,938,000.On average, 2 Wall Street analysts forecast CDMO's revenue for 2024 to be $8,745,986,615, with the lowest CDMO revenue forecast at $8,663,775,606, and the highest CDMO revenue forecast at $8,828,197,625. On average, 2 Wall Street analysts forecast CDMO's revenue for 2025 to be $10,608,382,175, with the lowest CDMO revenue forecast at $10,149,897,699, and the highest CDMO revenue forecast at $11,066,866,650.
In 2026, CDMO is forecast to generate $14,861,220,930 in revenue, with the lowest revenue forecast at $14,861,220,930 and the highest revenue forecast at $14,861,220,930.